Surrozen (SRZN) Cash & Current Investments (2020 - 2026)
Surrozen (SRZN) recorded quarterly Cash & Current Investments of $106.9 million in Q1 2026, up 19.79% quarter-over-quarter from $89.2 million in Q4 2025, and up 5.18% on a YoY basis from $101.6 million in Q1 2025.
Surrozen (SRZN) Cash & Current Investments (2020 - 2026) Analysis & Trends
Surrozen's Cash & Current Investments history runs 7 years deep, the most recent figure standing at $106.9 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 5.18% year-over-year to $106.9 million; the TTM figure through Mar 2026 stood at $106.9 million (up 5.18% YoY), while the FY2025 annual figure was $89.2 million, up 158.19% from the prior year.
- Cash & Current Investments was $106.9 million for Q1 2026 at Surrozen, up from $89.2 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $106.9 million in Q1 2026 to a low of $27.3 million in Q1 2024.
- Historically, Cash & Current Investments has averaged $66.7 million across 5 years, with a median of $75.8 million in 2022.
- The sharpest annual moves came in 2022 and 2024: Cash & Current Investments surged 391.72% in 2022, then tumbled 55.8% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $75.8 million in 2022, then tumbled by 52.47% to $36.0 million in 2023, then declined by 4.1% to $34.6 million in 2024, then jumped by 158.19% to $89.2 million in 2025, then advanced by 19.79% to $106.9 million in 2026.
- The last three Cash & Current Investments figures came in at $106.9 million (Q1 2026), $89.2 million (Q4 2025), and $81.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - | 106.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 106.91 Mn |
| Dec 31, 2025 | 89.25 Mn |
| Sep 30, 2025 | 81.30 Mn |
| Jun 30, 2025 | 90.40 Mn |
| Mar 31, 2025 | 101.65 Mn |
| Dec 31, 2024 | 34.57 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | 37.77 Mn |
| Mar 31, 2024 | 27.29 Mn |
| Dec 31, 2023 | 36.04 Mn |
| Sep 30, 2023 | 43.43 Mn |
| Jun 30, 2023 | 53.40 Mn |
| Mar 31, 2023 | 61.75 Mn |
| Dec 31, 2022 | 75.84 Mn |
| Sep 30, 2022 | 78.40 Mn |
| Jun 30, 2022 | 92.69 Mn |
| Mar 31, 2022 | 92.51 Mn |
| Dec 31, 2021 | 101.85 Mn |
| Sep 30, 2021 | 110.17 Mn |
| Jun 30, 2021 | 18.85 Mn |